EP4728073A1 - Formulation d'oligonucléotides - Google Patents

Formulation d'oligonucléotides

Info

Publication number
EP4728073A1
EP4728073A1 EP24822794.4A EP24822794A EP4728073A1 EP 4728073 A1 EP4728073 A1 EP 4728073A1 EP 24822794 A EP24822794 A EP 24822794A EP 4728073 A1 EP4728073 A1 EP 4728073A1
Authority
EP
European Patent Office
Prior art keywords
oligonucleotide
formulation
calcium
substance
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24822794.4A
Other languages
German (de)
English (en)
Inventor
Longcheng Li
Zubao GAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ractigen Therapeutics
Original Assignee
Ractigen Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ractigen Therapeutics filed Critical Ractigen Therapeutics
Publication of EP4728073A1 publication Critical patent/EP4728073A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des formulations d'oligonucléotides. En particulier, l'invention concerne des formulations d'oligonucléotides comprenant des oligonucléotides (tels que l'ASO, le petit ARNi, le petit ARNa) et le calcium, des procédés de préparation de ces formulations, et leur utilisation. Les formulations d'oligonucléotides ont une toxicité aiguë in vivo réduite (en particulier dans le système nerveux central) et une fenêtre de sécurité in vivo étendue pour les oligonucléotides, en particulier le conjugué lipidique, et ont ainsi de grandes perspectives d'application.
EP24822794.4A 2023-06-16 2024-06-14 Formulation d'oligonucléotides Pending EP4728073A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023100743 2023-06-16
PCT/CN2024/099219 WO2024255846A1 (fr) 2023-06-16 2024-06-14 Formulation d'oligonucléotides

Publications (1)

Publication Number Publication Date
EP4728073A1 true EP4728073A1 (fr) 2026-04-22

Family

ID=93851345

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24822794.4A Pending EP4728073A1 (fr) 2023-06-16 2024-06-14 Formulation d'oligonucléotides

Country Status (3)

Country Link
EP (1) EP4728073A1 (fr)
CN (1) CN121368633A (fr)
WO (1) WO2024255846A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013003875B1 (pt) * 2010-08-20 2021-10-05 Replicor Inc Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos
EP3511022A1 (fr) * 2012-05-10 2019-07-17 Adynxx, Inc. Formulations pour l'administration de principes actifs
MY168778A (en) * 2012-05-18 2018-12-04 Replicor Inc Oligonucleotide chelate complex-polypeptide compositions and methods
US20250297258A1 (en) * 2021-07-07 2025-09-25 Ractigen Therapeutics Oligonucleotide-based delivery vehicle for oligonucleotides agents and methods of use thereof

Also Published As

Publication number Publication date
WO2024255846A1 (fr) 2024-12-19
CN121368633A (zh) 2026-01-20

Similar Documents

Publication Publication Date Title
AU2022206704B2 (en) Nanoparticle formulations for delivery of nucleic acid complexes
AU2018203832B2 (en) RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy
CN115210377A (zh) 寡核苷酸组合物及其方法
EP3010514B1 (fr) Acide nucléique antisens a double brin ayant un effet de saut d'exon
JP7394753B2 (ja) アンチセンスオリゴマー化合物
RS56319B1 (sr) Oligonukleotidi koji moduliraju rnk sa poboljšanim karakteristikama za lečenje neuromišićnih poremećaja
AU2013285698A1 (en) Oligonucleotide for the treatment of muscular dystrophy patients
US20240117351A1 (en) Compositions and methods for inhibiting gene expression in the central nervous system
CN120699970A (zh) 用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法
WO2023245061A2 (fr) Conjugués lipidiques pour l'administration d'agents thérapeutiques au tissu du snc
TW202538051A (zh) 寡核苷酸的遞送載體及其使用方法
CN116769780A (zh) 用于抑制补体因子B表达的siRNA、其缀合物和药物组合物及其用途
WO2024255846A1 (fr) Formulation d'oligonucléotides
CN121816417A (zh) 双链寡核苷酸药剂和其用途
JP2025542580A (ja) 遺伝子サイレンシング技術としての、デオキシリボヌクレオチドが散在している短鎖二重鎖ｒｎａ、およびその使用
CN116497024A (zh) 一种核酸及其组合物、制备方法和用途
JP2024520556A (ja) 新規遺伝子サイレンシング技術としての短鎖二重鎖ｄｎａおよびその使用
JP2025542579A (ja) 遺伝子サイレンシング技術としての、デオキシリボヌクレオチドが散在している非対称短鎖二重鎖ｒｎａ、およびその使用
JP2025542581A (ja) アンチセンスＲＮＡ（ａｓＲＮＡ）技術およびその使用
KR20250059413A (ko) 눈에 투여하기 위한 이중 가닥 rna 분자
WO2026077086A1 (fr) Oligonucléotide double brin modifié et conjugué et composition associés
HK40078359A (en) Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
CN121127248A (zh) 用于抑制线粒体偕胺肟还原组分1 (MARC1)表达的RNAi剂、其药用组合物及使用方法
JP2026507286A (ja) 医薬組成物及びその使用
HK1203835B (en) Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260114

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR